Pheochromocytomas, PASS, and Immunohistochemistry

Abstract

Differentiation between malignant and benign pheochromocytomas of the adrenal gland traditionally relies on the presence of clinically detectable metastases. The PASS system for differentiating between benign and malignant pheochromocytomas is based on defined morphological criteria, of which some are related to tumour cell proliferation and survival. Immunohistochemical markers for important events in the cell cycle were explored in order to characterise differences in apoptosis, G1 checkpoints, and S phase in more detail. A panel consisting of p53, tenascin, bcl-2, pRb, cyclin D1, mcm2, and p27 was employed. Only for pRb a statistically significant difference between PASS 3 and less and PASS 4+ tumours was detected, indicating qualitative differences in the mitotic cycle, probably immediately before early S phase. These results are discussed in relation to similar studies in recent literature.

pheochromocytoma - PASS - p53 - Rb - cyclin D - bcl-2 - tenascin - mcm2 - p27

References

• 1 Thompson LDR, Young Jr WF, Kawashima A, Komminoth P, Tischler AS. Malignant adrenal phaeochromocytoma. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds) Pathology and Genetics of Tumours of Endocrine Organs. Kleihues P, Sobin LH (series eds) World Health Organisation Classification of Tumours, Lyon, France: IARC Press 2004: 147-150
• 2 Thompson LDR. Phaeochromocytomas of the Adrenal gland Scaled Score (PASS) to separate benign from malignant Neoplasms: A clinicopathological and immuno-phenotypic study of 100 cases.  Am J Surg Pathol. 2002;  26 551-556
• 3 Ramesh GT, Manna SK, Aggarwal BB, Jadhav AL. Lead activates nuclear transcription factor-kappa B, activator protein-1, and amino-terminal c-Jun kinase in phaeochromocytoma cells.  Toxicol Appl Pharmacol. 1999;  155 280-286
• 4 Lam KY, Lo CY, Wat NM, Luk JM, Lam KS. The clinicopathological features and importance of p53, Rb, and mdm2 expression in phaeochromocytomas and paragangliomas.  J Clin Pathol. 2001;  54 443-448
• 5 Gupta D, Shidham V, Holden J, Layfield L. Prognostic value of immunohistochemical expression of topoisomerase alpha II, MIB-1, p53, E-cadherin, retinoblastoma gene protein product, and HER-2/neu in adrenal and extra-adrenal phaeochromocytomas.  Appl Immunohistochem Mol Morphol. 2000;  8 267-274
• 6 Salmenkivi K, Heikkila P, Haglund C, Louhimo J, Arola J. Lack of histologically suspicious features, proliferative activity, and p53 expression suggest benign diagnosis in phaeochromocytomas.  Histopathology. 2003;  43 62-71
• 7 Saraste A, Pulkki K. Morphologic and biochemical hallmarks of apoptosis.  Cardiovas Res. 2000;  45 528-537
• 8 Cobrinik D, Francis RO, Abramson DH, Lee TC. Rb induces a proliferative arrest and curtails Brn-2 expression in retinoblastoma cells.  Mol Cancer. 2006;  5 72
• 9 Cetani F, Pardi E, Viacava P, Viacava P, Pollina GD, Fanelli G, Picone A, Borsari S, Gazzerro E, Miccoli P, Berti P, Pinchera A, Marcocci C. A reappraisal of the Rb1 gene abnormalities in the diagnosis of parathyroid cancer.  Clin Endocrinol (Oxf). 2004;  60 99-106
• 10 Yang Y, Wenjun B, Haegebarth A, Tyner AL. Differential Regulation of D-Type Cyclins in the Mouse Intestine.  Cell Cycle. 2006;  5 180-183
• 11 Wang DG, Johnston CF, Marley JJ, Phenix KV, Atkinson AB, Russell CFJ, Buchanan KD. Expression of the apoptosis- suppressing gene bcl-2 phaeochromocytomas is associated with the expression of c-myc.  J Clin Endorinol Metab. 1997;  82 1949-1952
• 12 Hanahan D, Weinberg RA. The Hallmarks of Cancer.  Cell. 200;  100 57-70
• 13 Hockenberry DM, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death.  Nature. 1990;  348 334-336
• 14 Chang F, Syrjanen S, Tervahauta A, Syrjanen K. Tumorigenesis associated with p53 tumour suppressor gene.  Br J Cancer. 1993;  68 653-661
• 15 Reed JC, Meister L, Tanaka S, Cuddy M, Yum S, Geyer C, Pleasure D. Differential expression of Bcl-2 proto-oncogene in neuroblastoma and other human tumour cell lines of neural origin.  Cancer Res. 1991;  51 6529-6538
• 16 Wang DG, Johnston CF, Marley JJ, Phenix KV, Atkinson AB, Russell CFJ, Buchanan KD. Expression of the apoptosis- suppressing gene bcl-2 phaeochromocytoma is associated with the expression of c-myc.  J Clin Endorinol Metab. 1997;  82 1949-1952
• 17 Chiquet-Ehrismann R, Mackie EJ, Pearson CA, Sakakura T. Tenascin: extracellular matrix protein involved in tissue interactions during fetal development and oncogenesis.  Cell. 1986;  47 131-139
• 18 Salmenkivi K, Heikkila P, Haglund C, Arola J. Malignancy in Phaeochromocytomas.  APMIS. 2004;  112 551-559
• 19 Kimura N, Watanabe T, Noshiro T, Shizawa S, Miura Y. Histological grading of adrenal and extra-adrenal phaeochromocytomas and relationship to prognosis: a clinicopathological analysis of 116 adrenal phaeochromocytomas and 30 extra-adrenal sympathetic paragangliomas including 38 malignant tumors.  Endocr Pathol. 2005;  16 23-32
• 20 August C, August K, Schroeder S. CGH and CD 44/MIB-1 immunohistochemistry are helpful to distinguish metastasized from non-metastasized sporadic phaeochromocytomas.  Modern Pathol. 2004;  17 1119-1128
• 21 Liu TH, Chen YJ, Wu SF, Gao J, Jiang WJ, Lu ZH, Guan J, Wei SZ, Luo YF, Cao JL, Wan JW. Distinction between benign and malignant phaeochromocytomas.  Zhonghua Bing Li Xue Za Zhi. 2004;  33 198-202
• 22 Kajor M, Ziaja J, Lange D, Król R, Ciupiñska-Kajor M, Turska-d’Amico M, Maka B, Cierpka L. Analysis of morphology of adrenal phaeochromocytoma as regards their potential malignancy.  Endokrynol Pol. 2005;  56 911-916
• 23 Sporny S, Musiał J. Markers of malignancy in phaeochromocytomas.  Endokrynol Pol. 2005;  56 946-951
• 24 Gao B, Meng F, Bian W, Chen J, Zhao H, Ma G, Shi B, Zhang J, Liu Y, Xu Z. Development and validation of phaeochromocytoma of the adrenal gland scaled score for predicting malignant phaeochromocytomas.  Urology. 2006;  68 282-286
• 25 Bilek R, Safarik L, Ciprova V, Vlcek P, Lisa L. Chromogranin A, a Member of Neuroendocrine Secretory Proteins as a Selective Marker for Laboratory Diagnosis of Phaeochromocytoma.  Physiol Res. 2008;  57 ((Suppl 1)) S171-S179
• 26 Strong VE, Kennedy T, Al-Ahmadie H, Tang L, Coleman J, Fong Y, Brennan M, Ghossein RA. Prognostic indicators of malignancy in adrenal phaeochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis.  Surgery. 2008;  143 759-768
• 27 Anonymous . http://mitel.dimi.uniud.it/udipath/tpdb/show.php?id=94%20&%20view=%20accessed%20231008
• 28 McNicol AM. Personal communication. 2008; 
• 29 Eisenhofer G, Bornstein SR, Brouwers FM, Cheung NK, Dahia PL, de Krijger RR, Giordano TJ, Greene LA, Goldstein DS, Lehnert H, Manger WM, Maris JM, Neumann HP, Pacak K, Shulkin BL, Smith DI, Tischler AS, Young WF Jr. Malignant pheochromocytoma: current status and initiatives for future progress.  Endocr Relat Cancer. 2004;  11 423-436
• 30 Favier J, Plouin PF, Corvol P, Gasc JM. Angiogenesis and vascular architecture in phaeochromocytomas: distinctive traits in malignant tumors.  Am J Pathol. 2002;  161 1235-1246
• 31 Cryns VL, Thor A, Xu H-J, Hu SX, Wierman ME, Vickery  Jr AL, Benedict WF, Arnold A. Loss of the retinoblastoma tumor suppressor gene in parathyroid carcinoma.  N Engl J Med. 1994;  330 757-761
• 32 Dotzenrath C, The BT, Farnebo F, Cupisti K, Svensson A, Toell A, Goretzki P, Larsson C. Allelic Loss of the Retinoblastoma Tumor Suppressor Gene: A Marker for Aggressive Parathyroid Tumors?.  J Clin Endocrinol Metab. 1996;  81 3194-3196
• 33 de Krijger RD, v d Harst ED, Ham FD, Stijnen T, Dinjens WN, Koper JW, Bruining HA, Lamberts SW, Bosman FT. Prognostic value of p53, bcl-2, and c-erbB-2 protein expression in phaeochromocytomas.  J Pathol. 1999;  188 51-55
• 34 Dahia PL, Aguiar RC, Tsanaclis AM, Bendit I, Bydlowski SP, Abelin NM, Toledo SP. Molecular and immuno-histochemical analysis of p53 in phaeochromocytomas.  Br J Cancer. 1995;  72 1211-1213
• 35 Clarke MR, Weyant RJ, Watson CG, Carty SE. Prognostic markers in phaeo-chromocytoma.  Hum Pathol. 1998;  29 522-526
• 36 Thompson LDR. Personal communication. 2006; 
• 37 Tischler AS, Kimura N, Mcnicol AM. Pathology of phaeochromocytoma and extra-adrenal paraganglioma.  Ann N Y Acad Sci. 2006;  1073 557-570

Correspondence